Skip to content
Home/Companies/Biotech/arGEN-X
arGEN-X

arGEN-X

Biotech·Netherlands·Exited 2017·Held 8yr
Entry
2009
Hold
8yr
Exit
2017

Who owns arGEN-X?

arGEN-X was owned by Omnes Capital through Omnes Co-Investment (2008 vintage) from 2009 to 2017, exited via IPO.

Hand-verified · updated 2026-04-21

Omnes Capital
Investor
Omnes Capital
Omnes Co-Investment · 2008 · Buyout

Key facts

HQNetherlands
SectorBiotech
Websiteargenx.nl
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2017

More from Omnes Co-Investment

Other portfolio companies in the same fund.

CBA
Active
TMTFrance· 2024
Arrow Global
Arrow Global
Active
Business ServicesUK· 2023
Avania
Avania
Active
MedTechNetherlands· 2022
Ecovadis
Ecovadis
Active
TMTFrance· 2022
Scality
Scality
Active
AI/MLUS· 2021
UTAC CERAM Millbrook
Active
Business ServicesFrance· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track arGEN-X

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on arGEN-X.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue